NIV and HFNC failureMANAGEMENT

RESPIRATORY PRESENTATIONS · 12 SECTIONS

⚲

499 items

☷ Legend

01Approach to the Critical Patient/attcp68

Immediate Priorities and Triage

›Stabilization priorities

›Airway protection concerns

›Vomiting or active regurgitation on non-invasive support

›Copious secretions overwhelming clearance

›GCS decline precluding mask cooperation

›Breathing failure concerns

›SpO2 persistently below target despite escalating HFNC or NIV settings

›Rising respiratory rate on non-invasive support rather than falling

›Rising PaCO2 with pH below 7.25 despite an adequate NIV trial

›Circulatory concerns

›New hypotension after NIV or CPAP initiation

›Peri-intubation arrest risk building silently while a failing trial continues

›High risk phenotypes for early failure

›Undifferentiated hypoxemic respiratory failure with no clear cardiogenic or COPD driver

›Multiorgan dysfunction accompanying respiratory failure

›Immunocompromised host with diffuse infiltrates

›Immediate monitoring

›Continuous pulse oximetry with waveform quality check

›Continuous cardiac monitoring

›Frequent bedside reassessment of work of breathing and mental status

›Serial blood gas at defined timepoints rather than a single baseline value

›Escalation triggers

›Resuscitation bay or ICU team activation

›pH below 7.25 not improving after an adequate trial

›Respiratory rate rising rather than falling on support

›New altered mental status on support

›Immediate airway team activation

›Apnea or agonal breathing

›Inability to tolerate the interface due to agitation or obtundation

›Hemodynamic collapse

Buying Time Versus Delaying a Necessary Intubation

›The central decision framework

›Non-invasive support is a time-limited trial with predefined reassessment points, not an open-ended therapy

›A trial without a stated reassessment time is a decision deferred, not a decision made

›Early intubation after recognized failure has better outcomes than delayed intubation

›Cohort data on high-flow failure show delayed intubation carries roughly double the mortality risk of early intubation after failure is recognized

›The harm accrues from ongoing high respiratory effort and progressive lung injury during the delay, not from intubation itself

›Decide to intubate while the patient is still stable enough to tolerate the procedure

›Waiting for peri-arrest physiology converts an elective airway into a crash airway

›Pre-brief the team and prepare equipment as soon as a trial shows an unfavorable trajectory, before failure is confirmed

›Distinguishing a failing trial from a slow but real response

›Improving trajectory

›Falling respiratory rate

›Rising pH or falling PaCO2 on serial gas

›Improving mentation and reduced accessory muscle use

›Failing trajectory

›Unchanged or rising respiratory rate at the scheduled reassessment

›Persistent or worsening acidosis at the scheduled reassessment

›Poor tolerance of the interface or worsening agitation

›New or worsening altered mental status

›Reassessment timepoints that must be scheduled explicitly

›HFNC ROX index reassessment at 2, 6, and 12 hours after initiation

›NIV clinical and blood gas reassessment at 1 hour and again at 2 hours after initiation

›Continuous clinical reassessment of work of breathing and tolerance every 15 to 30 minutes during the first hour on either device

Key Concepts and PITFALLS

›Core physiologic concepts

›Non-invasive support treats work of breathing and gas exchange, it does not treat the underlying disease

›Failure to treat the precipitant in parallel guarantees eventual escalation

›A device that is well tolerated is not the same as a device that is working

›Comfort without physiologic improvement is a failing trial

›Common pitfalls

›Drifting rather than deciding

›Serial small upward titrations without a defined ceiling or a defined failure point

›No documented reassessment time when the trial began

›Confusing palliative intent with a failing curative trial

›Escalation criteria differ fundamentally between the two and must be set at initiation

›Treating an intolerant patient with sedation instead of reassessing the diagnosis or the interface

›Sedation can mask the very findings that indicate escalation is needed

›Missing an occult pneumothorax converting to tension physiology under positive pressure

›Sudden hypotension or unilateral breath sound loss on NIV or HFNC support

02History/hx38

Presenting Pattern and Trial-of-Support Trajectory

›Symptom and trajectory pattern

›Time since non-invasive support was started

›Trend since initiation

›Improving, unchanged, or worsening dyspnea

›Improving, unchanged, or worsening ability to speak

›Prior settings changes

›Number of flow, FiO2, or pressure escalations already attempted

›Time interval between escalations

›Precipitant clues

›Recent viral or bacterial respiratory illness

›New orthopnea or paroxysmal nocturnal dyspnea

›Chest pain or ischemic equivalent

›Aspiration event

›Recent sedative, opioid, or alcohol exposure

Risk Factors for a Failing Trial

›Baseline respiratory reserve

›Home oxygen or home non-invasive ventilation use

›Prior ICU admission or intubation for respiratory failure

›Neuromuscular disease or chest wall restriction

›Presentation severity clues

›Symptom duration before presentation

›Rapid onset over hours favors a reversible precipitant

›Days of worsening before presentation favors a slower failing course

›Prior non-invasive support failure history

›Prior NIV or HFNC intolerance

›Prior rapid intubation despite a trial

›Immunocompromise concern

03Physical Exam/exam31

Work of Breathing and Tolerance Assessment

›Respiratory pattern

›Respiratory rate trend since support started

›Accessory muscle use trend since support started

›Paradoxical abdominal motion

›Speech capacity while on the device

›Interface tolerance

›Synchrony with device cycling

›Agitation or repeated mask removal

›Air swallowing or gastric distension

›Mental status trend

›Somnolence or new confusion

›Agitation out of proportion to hypoxemia

›Hemodynamic findings

›Blood pressure trend after initiation

›New tachycardia or new arrhythmia on the monitor

Mask Fit, Skin, and Device-Specific Findings

›Interface fit

›Visible air leak around the seal

›Eye irritation from leak toward the eyes

›Skin integrity

›Nasal bridge erythema or early pressure injury

›Ear or cheek pressure points under head straps

›Device-specific findings

›HFNC nares irritation or epistaxis

›NIV abdominal distension from aerophagia

PITFALLS

›Misleading findings

04Differential Diagnosis/ddx25

Causes of a Failing Trial, Ranked by Prevalence-Weighted Danger

›Most common dangerous causes

›Progressive pump failure or cardiogenic shock underlying the pulmonary edema

›ICD-10 I50.1

›Evolving ARDS or worsening hypoxemic failure

›ICD-10 J80

›Undertreated precipitant, for example ongoing bronchospasm or undertreated infection

›Occult pneumothorax converting to tension physiology under positive pressure

›ICD-10 J93.0

›Interface and device problems mimicking physiologic failure

›Poor mask fit or major leak reducing effective pressure or flow

›Circuit disconnection or inadequate flow delivery

›Patient-device asynchrony

›Less common but must-not-miss causes

›Pulmonary embolism with respiratory failure

›ICD-10 I26.99

›Upper airway obstruction not evident at initial exam

›Aspiration during the trial

›Oversedation or opioid effect blunting respiratory drive

Diagnoses That Should Redirect the Approach Entirely

›Wrong modality for the physiology

›NIV trialed in undifferentiated hypoxemic failure without a cardiogenic or hypercapnic driver

›NIV trialed in severe asthma with poor air movement rather than standard status asthmaticus therapy

›Contraindication missed at initiation

›Unrecognized vomiting risk or altered airway protection

›Unrecognized facial trauma or recent upper airway surgery

›Unrecognized hemodynamic instability

05Laboratory Tests/lt25

Serial Blood Gas Interpretation

›Blood gas strategy

›Baseline gas at initiation

›Venous blood gas acceptable for pH and PaCO2 trend

›Arterial blood gas when precise oxygenation or PaO2 to FiO2 ratio is needed

›Repeat gas at the scheduled reassessment time

›1 hour and 2 hours for NIV

›Aligned with ROX index checks for HFNC when oxygenation is the primary question

›Interpretation targets

›Rising pH and falling PaCO2 support continuing the trial

›Persistent pH below 7.25 supports escalation to intubation

›PaO2 to FiO2 ratio

›Used to grade hypoxemic severity and trend response

›Falling ratio despite escalating FiO2 supports a failing trial

Lab Interpretation Traps

›Traps that redirect the diagnosis

›Venous blood gas obtained after brief removal of HFNC can understate the degree of hypoxemia present on the device

›Elevated lactate from high dose nebulized beta agonist use can be mistaken for sepsis physiology

›Normal pulse oximetry in carbon monoxide poisoning or significant methemoglobinemia despite true hypoxemia

›Venous PCO2 may underestimate arterial PCO2 in shock states with poor perfusion

›Electrolyte and infection labs

›Potassium and magnesium for arrhythmia risk with high dose beta agonist or diuretic use

›ECG for QT prolongation or U waves if hypokalemia develops from high dose beta agonist or diuretic therapy

›Glucose

›Steroid induced hyperglycemia risk

›Hypoglycemia concern in a lethargic or poorly feeding infant with respiratory failure

›Lactate and blood cultures if sepsis is a plausible driver of the underlying failure

06Diagnostic Tests/dt45

Scoring Systems

›HFNC failure prediction

›ROX index

›Defined as SpO2 divided by FiO2, divided by respiratory rate

›Assessed at 2, 6, and 12 hours after HFNC initiation

›ROX below 2.85 at 2 hours predicts a high risk of failure

›ROX below 3.47 at 6 hours predicts a high risk of failure

›ROX below 3.85 at 12 hours predicts a high risk of failure

›ROX at or above 4.88 at any of these timepoints predicts a low risk of failure

›Use limitation

›Derived in pneumonia related hypoxemic failure, extrapolation to other etiologies is less validated

›NIV failure prediction

›HACOR score

›Components heart rate

›Components acidosis, meaning pH

›Components consciousness level

›Components oxygenation, meaning PaO2 to FiO2 ratio

›Components respiratory rate

›Score above 5 at 1 hour after NIV initiation predicts a high risk of NIV failure

›Use limitation

›A single early score should prompt closer reassessment, not an automatic decision alone

MRI

›Role

›Not routine for evaluating NIV or HFNC failure itself

›Reserved for suspected central hypoventilation or spinal cord pathology as the underlying driver

›Practical limitation

›Standard non-invasive support equipment is not MRI safe

›A patient requiring ongoing NIV or HFNC cannot safely enter a standard MRI suite without an MRI compatible ventilation strategy

07Disposition/dispo20

Level of Care and Escalation Timing

›ICU level indications

›Any confirmed NIV or HFNC failure requiring intubation

›Persistent pH below 7.25 despite an adequate NIV trial

›ROX index below the failure threshold at the scheduled timepoint

›Hemodynamic instability developing on support

›Step down or high acuity ward indications

›Successful HFNC or NIV trial with a stable and improving trajectory

›Ongoing need for close respiratory monitoring without ICU-level instability

›Ward indications

›Resolved precipitant with only low flow oxygen requirement remaining

Transfer Criteria

›Transfer indications from a non-tertiary site

›Need for invasive mechanical ventilation without local ICU capacity

›Refractory hypoxemia raising the possibility of advanced support such as ECMO

›Anticipated difficult airway without local airway backup resources

›Transfer logistics

›Support must continue during transport, HFNC or NIV equivalent capability in the transport vehicle

›Airway equipment and a clinician capable of emergent intubation must accompany an unstable transfer

Ceiling of Care Disposition

›Disposition when NIV is the agreed ceiling

›Appropriate location for comfort-focused non-invasive support, which may be a ward or hospice-capable unit rather than ICU

›Clear documentation of the agreed ceiling accompanying every handoff

08Treatment/t141

HFNC Setup, Titration, and Failure Recognition

›Initial setup

›Flow rate

›Adult initial flow 40 to 60 L/min

›Pediatric initial flow approximately 2 L/kg/min up to 20 kg, then smaller weight-tiered increments toward an adult ceiling of 60 L/min

›Verify against current pediatric guideline before use

›FiO2

›Initial FiO2 40% to 60% for moderate hypoxemia, up to 100% for severe hypoxemia

›Titrate FiO2 down to the lowest value maintaining the SpO2 target once stable

›Titration principle

›Increase flow first for dyspnea and work of breathing

›Increase FiO2 for isolated hypoxemia once flow is adequate

›Failure recognition and reassessment

›ROX index at 2, 6, and 12 hours as above

›Escalate to NIV or intubation if ROX falls below threshold at the scheduled check

›Escalate if respiratory rate rises rather than falls despite an adequate flow trial

NIV Indications, Contraindications, and Initial Settings

›Strong evidence indications

›COPD exacerbation with acute hypercapnic respiratory acidosis

›Class I recommendation in major society guidance

›Reduces need for intubation and reduces mortality

›Acute cardiogenic pulmonary edema

›Class I recommendation in major society guidance

›Reduces need for intubation

›Reasonable but weaker evidence indications

›Immunocompromised patients with acute hypoxemic respiratory failure

›An early trial has been associated with lower intubation and lower ICU mortality in landmark study data, though evidence is less robust than for COPD or cardiogenic edema

›Weak or potentially harmful indications

›Undifferentiated hypoxemic respiratory failure without a cardiogenic or hypercapnic driver

›Landmark trial data comparing high-flow oxygen, standard oxygen, and face mask NIV in this population found intubation rates of roughly 38%, 47%, and 50% respectively, disfavoring routine NIV in this group

›Asthma exacerbation

›Evidence does not support routine use, if trialed as an adjunct in severe bronchospasm it should not delay standard bronchodilator and steroid therapy or a timely intubation decision

›Absolute contraindications

›Inability to protect the airway

›Active vomiting or high aspiration risk

›Hemodynamic instability

›Facial trauma or recent facial or upper airway surgery

›Fixed upper airway obstruction

›Initial settings

›COPD hypercapnic exacerbation

›IPAP 10 to 15 cmH2O

›Titrate by 2 to 3 cmH2O every 5 to 10 minutes for ventilation

›EPAP 4 to 6 cmH2O

›Backup rate 10 to 16 breaths per minute when available

›Cardiogenic pulmonary edema

›CPAP 8 to 12 cmH2O

›If CPAP not tolerated, BiPAP with EPAP 8 to 12 cmH2O and modest additional inspiratory pressure support

NIV Titration, Monitoring, and Failure Predictors

›Response targets

›Improved dyspnea and reduced accessory muscle use within 30 to 60 minutes

›Rising pH and falling PaCO2 on repeat gas at 1 to 2 hours

›Failure predictors requiring escalation

›Persistent acidosis, pH below 7.25 not improving at the 1 to 2 hour reassessment

›Respiratory rate unimproved or rising at the 1 to 2 hour reassessment

›Poor interface tolerance or worsening agitation

›New or worsening altered mental status

›HACOR score above 5 at 1 hour

›Troubleshooting a trial that appears not to be working

›Check for mask leak or poor fit before declaring physiologic failure

›Check circuit connections and confirm delivered pressure or flow at the device

›Reassess for an unrecognized contraindication or an alternative diagnosis, for example new pneumothorax

›If no correctable device problem is found, treat this as true failure and proceed to escalation

The Decision to Intubate: Timing and Pre-Oxygenation

›Indications for intubation

›Confirmed NIV or HFNC failure by the criteria above

›Inability to protect the airway

›Refractory hypoxemia despite an adequate trial

›Severe hypercapnic acidemia, pH below 7.20 with clinical fatigue

›Timing principle

›Commit to intubation once failure criteria are met rather than continuing to titrate settings

›Prepare equipment and call for airway support as soon as the trajectory looks unfavorable, before the patient is peri-arrest

›Pre-oxygenation using the non-invasive device itself

›Continue NIV at FiO2 100% for 3 to 5 minutes immediately before induction when feasible

›Continue HFNC through induction and laryngoscopy as an apneic oxygenation source at 40 to 60 L/min

›RSI considerations specific to this population

›Anticipate gastric insufflation from prior NIV use, increasing aspiration risk at induction

›Anticipate a hemodynamically fragile induction in a patient with high sympathetic drive prior to intubation

›Reduced induction doses may be warranted in this fragile physiology

Sedation, Analgesia, and Hemodynamic Support During Escalation

›Induction agents

›Etomidate IV 0.3 mg/kg

›Preferred for hemodynamic neutrality

›Ketamine IV 1 to 2 mg/kg

›Reasonable alternative, caution with severe hypertension or active ischemia

›Propofol IV 1 to 2 mg/kg

›Hypotension risk, reduce dose in a hemodynamically fragile patient

›Paralytics

›Succinylcholine IV 1 to 1.5 mg/kg

›Contraindicated with hyperkalemia, neuromuscular disease, or major burns after 24 to 48 hours

›Rocuronium IV 1.2 mg/kg

›Longer paralysis duration to plan around

›Post-intubation analgesia and sedation

›Fentanyl IV 25 to 100 mcg bolus

›Repeat every 5 minutes to comfort and ventilator synchrony

›Propofol infusion 10 to 50 mcg/kg/min

›Titrate every 5 minutes to target sedation level

›Monitor for hypotension every 5 to 15 minutes during titration

›Dexmedetomidine infusion 0.2 to 1.5 mcg/kg/hr

›Monitor for bradycardia

›Hemodynamic support during and after escalation

›Norepinephrine infusion 0.05 to 1 mcg/kg/min

›Titrate every 5 to 15 minutes to a mean arterial pressure at or above 65 mmHg

›Have access available before induction in a patient at risk of peri-intubation hypotension

Iatrogenic Harms of Routine ED Interventions in a Failing Trial

›Walking the standard intervention list

›Intubation

›Not itself harmful when timed early, but delayed intubation after recognized failure carries substantially higher mortality than early intubation

›Sedation

›Sedating an intolerant patient to force continued non-invasive support can mask the mental status decline that should trigger escalation instead

›Fluid loading

›Contraindicated as an empiric response to hypotension in cardiogenic pulmonary edema on NIV, an empiric bolus can precipitate flash pulmonary edema and cardiac arrest

›In hypoxemic or sepsis-associated failure, judicious fluid with early vasopressor support is preferred over aggressive volume loading

›Oxygen

›Hyperoxia beyond the SpO2 target should be avoided, it does not improve outcomes and worsens hypercapnia in CO2 retainers

›An exception is the brief pre-oxygenation window immediately before intubation, where a high FiO2 is appropriate

›Vasopressors

›Positive intrathoracic pressure from NIV or CPAP reduces preload and can unmask hypotension in a volume-depleted or septic patient, vasopressor access should be ready before initiating support in a borderline patient

›Overt hemodynamic instability requiring vasopressors is itself a relative contraindication to a first NIV trial

›Mechanical circulatory support, including intra-aortic balloon pump

›Not routinely required for isolated NIV or HFNC failure, but when cardiogenic shock coexists, positive pressure ventilation reduces afterload and is generally favorable

›Mask leak and patient agitation on NIV can interfere with ECG-triggered balloon counterpulsation timing, coordinate ventilation strategy with critical care when a balloon pump is in place

›Anticoagulation

›If pulmonary embolism is the suspected driver, initiating anticoagulation should not be delayed by a prolonged non-invasive trial

›Therapeutic anticoagulation should prompt caution around line placement and RSI planning if intubation becomes necessary

›Fibrinolysis

›Not indicated for standard NIV or HFNC failure, relevant only if massive pulmonary embolism with shock is the underlying driver, where deterioration during a non-invasive trial should not delay the decision

›Analgesia

›Untreated pain increases work of breathing and can worsen a failing trial, but opioids blunt respiratory drive and must be titrated cautiously with close respiratory monitoring

›In a patient trending toward intubation, opioid dosing should not be increased as a substitute for escalation

Palliative and Ceiling-of-Care Use of NIV

›Distinguishing this indication from a failing curative trial

›NIV as ceiling of care is a deliberate choice made with the patient or surrogate before or at initiation, not a fallback discovered after failure

›Escalation criteria differ, deterioration on ceiling-of-care NIV prompts a shift to comfort measures rather than intubation

›Comfort-focused management on this pathway

›Opioid titration for dyspnea as the primary therapy once escalation has been declined

›Interface selection favoring tolerance and comfort over strict pressure or flow targets

›Ongoing communication with family about the expected course

Mask Fit, Skin Injury, and Infection Control

›Interface fit and leak management

›Correct sizing before assuming physiologic failure

›Rotating or alternating interface type to reduce continuous pressure on the same skin area

›Skin injury prevention

›Prophylactic barrier dressing over the nasal bridge for anticipated prolonged NIV use

›Skin check for pressure injury every 2 to 4 hours during continuous use

›Aerosol and infection control

›NIV and HFNC are aerosol generating procedures

›Airborne or droplet precautions and an appropriately ventilated room for suspected transmissible respiratory infection

›N95 or equivalent respirator for staff during use in a suspected transmissible infection

›Viral filter on the expiratory limb where available

09Special Populations/sp40

Pregnancy

›Physiologic considerations

›Reduced functional residual capacity increasing hypoxemia risk

›Higher baseline oxygen consumption

›Oxygenation target

›SpO2 at least 95% as the typical fetal oxygenation goal, an exception to the general 92% to 96% target

›Device use

›HFNC and NIV are both used in pregnancy when indicated, aspiration risk should be weighed given delayed gastric emptying

›Escalation threshold

›A lower threshold to involve obstetric and anesthesia teams early given the physiologic reserve is reduced

Geriatric

›Physiologic reserve

›Earlier fatigue and faster decompensation than younger adults

›Comorbid heart failure and COPD overlap common, complicating the choice of modality

›Medication sensitivity

›Higher hypotension risk with induction agents and sedative infusions

›Delirium risk with benzodiazepines and with hypercapnia or hypoxemia itself

›Goals of care emphasis

›Advance directive and ceiling-of-care discussion should occur early rather than only after a failing trial

Pediatrics

›Age-specific considerations

›Age-specific respiratory rate thresholds rather than a single adult cutoff for tachypnea

›Common etiologies differ from adults, for example bronchiolitis and croup rather than COPD

›HFNC dosing

›Weight-based flow as above, approximately 2 L/kg/min up to 20 kg

›Verify against current pediatric guideline before use

›Resuscitation doses if deterioration occurs

›Epinephrine IV or IO 0.01 mg/kg of the 0.1 mg/ml concentration for arrest

10Background/b31

Epidemiology

›Failure rates by modality and etiology

›NIV failure in COPD exacerbation with hypercapnic acidosis occurs in roughly 15% to 20% of appropriately selected patients

›In a landmark trial of undifferentiated acute hypoxemic respiratory failure, intubation occurred in roughly 38% of patients assigned high-flow oxygen, 47% assigned standard oxygen, and 50% assigned face mask NIV

›NIV failure rates in acute hypoxemic respiratory failure outside a cardiogenic or hypercapnic pattern are substantially higher than in COPD

›Outcome impact of delayed recognition

›Cohort studies of high-flow failure report ICU mortality roughly two-fold higher when intubation is delayed after failure is recognized compared with early intubation

›Immunocompromised subgroup

›An early NIV trial in immunocompromised patients with hypoxemic failure and pulmonary infiltrates has been associated with lower rates of intubation and lower ICU mortality than standard oxygen therapy in landmark study data

Pathophysiology

›Patient self-inflicted lung injury

›Mechanism

›High respiratory drive in a spontaneously breathing patient generates large negative pleural pressure swings and large transpulmonary pressure swings

›These swings drive excessive tidal volumes and regional lung stress even without positive pressure ventilation

›Increased pulmonary vascular transmural pressure worsens edema formation in an already injured lung

›Clinical consequence

›Prolonging a failing HFNC or NIV trial can allow ongoing lung injury to accumulate before intubation, compounding the harm of delayed escalation

›Failure mechanisms by modality

›HFNC failure reflects inadequate flow or FiO2 to overcome the patient's oxygen demand and work of breathing

›NIV failure in hypercapnic disease reflects inadequate alveolar ventilation despite pressure support, or fatigue outpacing the support provided

›NIV failure in hypoxemic disease reflects a shunt physiology that positive pressure alone cannot correct

Therapeutic Considerations

›Positive pressure benefits

›Reduced work of breathing

›Reduced preload and afterload benefiting cardiogenic pulmonary edema

›Improved alveolar ventilation in hypercapnic disease

›Positive pressure risks

›Barotrauma and pneumothorax

11Patient Discharge Instructions/pdi19

copy discharge instructions

›Discharge plan for a resolved episode of respiratory failure that required only brief non-invasive support

›Medication plan

›Inhaler or nebulizer technique review

›Steroid course completion if prescribed

›Diuretic dose adjustment if heart failure was the cause

›Home monitoring numbers to track

›Home oxygen saturation target if a home oximeter is provided

›Weight check daily if heart failure was the cause, call if weight rises more than 1 to 2 kg in a day

›Temperature check if fever prompted this episode, call if above 38.0 degrees Celsius

›Return to ED immediately if

›Trouble breathing at rest or unable to speak in full sentences

›Lips or fingertips turning blue or gray

›New confusion or extreme sleepiness

›Chest pain or fainting

›Oxygen saturation below the number given at discharge despite using home oxygen as prescribed

›Follow up

›Primary care or pulmonology within 2 to 7 days

›Cardiology follow up within 1 to 2 weeks if heart failure was the cause

›Home oxygen equipment and non-invasive ventilation equipment arrangement confirmed before leaving if newly prescribed

12References/r16

Clinical Guidelines and Evidence

›ATS ERS clinical practice guideline on noninvasive ventilation for acute respiratory failure

›NIV recommended in acute hypercapnic COPD exacerbation with acidemia

›NIV recommended in cardiogenic pulmonary edema

›Conditional, weaker-evidence support for immunocompromised patients with hypoxemic failure

›Global Initiative for Chronic Obstructive Lung Disease COPD report

›NIV indications and failure criteria in acute exacerbation

›Surviving Sepsis Campaign guidelines

›Early vasopressor and judicious fluid strategy relevant when sepsis contributes to a failing trial

Decision Tools and Landmark Trials

›ROX index derivation and validation studies

›Developed and validated primarily in pneumonia-related hypoxemic respiratory failure treated with HFNC

›HACOR score studies for NIV failure prediction

›Validated at the 1 hour timepoint after NIV initiation

›FLORALI trial comparing high-flow oxygen, standard oxygen, and NIV in acute hypoxemic respiratory failure

›Informs the caution against routine NIV use in undifferentiated hypoxemic failure

›Hilbert and colleagues, early NIV trial in immunocompromised patients with acute respiratory failure

›Informs the reasonable-but-weaker-evidence indication in immunocompromised hosts

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed September 13, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.